Thiopurines in the Treatment of Childhood Acute Lymphoblastic Leukemia and Genetic Variants of the Thiopurine S-Methyltransferase Gene

  • Martin Stanulla
  • Elke Schaeffeler
  • Matthias Schwab
Part of the Cancer Drug Discovery and Development™ book series (CDD&D)

Summary

The thiopurines 6-mercaptopurine (6-MP) and 6-thioguanine (6-TG) are essential components of treatment protocols for childhood acute lymphoblastic leukemia (ALL). In the past 25 years, considerable insights into thiopurine pharmacology have been gained through continuing research efforts which have led to the development of strategies for improving efficacy and reducing toxicity associated with 6-MP and 6-TG application. One important route of metabolism for thiopurines is methylation by the enzyme thiopurine S-methyltransferase (TPMT). The gene coding for TPMT is subject to phenotypically relevant genetic variation, with heterozygous individuals having intermediate TPMT activity, and homozygous variant individuals having low TPMT activity. In this chapter, we review the role of thiopurines in the treatment of childhood ALL and provide an overview of strategies aimed at optimization of thiopurine application by therapeutic drug monitoring of thiopurine metabolites and geno- or phenotyping of TPMT.

Key Words

Thiopurines mercaptopurine thioguanine thiopurine S-methyl- transferase TPMT leukemia acute lymphoblastic leukemia childhood treatment genetic variation genetic polymorphism 

References

  1. 1.
    Pui CH, Evans WE. Treatment of childhood acute lymphoblastic leukemia. N Engl J Med 2006;354:166–178.PubMedCrossRefGoogle Scholar
  2. 2.
    Schrappe M, Reiter A, Zimmermann M et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Leukemia 2000;14:2205–2222.PubMedCrossRefGoogle Scholar
  3. 3.
    Silverman LB, Sallan SE. Newly diagnosed childhood acute lymphoblastic leukemia: update on prognostic factors and treatment. Curr Opin Hematol. 2003;10:290–296.PubMedCrossRefGoogle Scholar
  4. 4.
    Pinkel, D. Five-year follow-up of “Total Therapy” of childhood lymphocytic leukemia. JAMA 1971;216:648–652.CrossRefGoogle Scholar
  5. 5.
    Riehm H, Gadner H, Henze G et al. The Berlin childhood acute lymphoblastic leukemia therapy study, 1970–1976. Am J Pediatr Hematol Oncol 1980;2:299–306.Google Scholar
  6. 6.
    Rivera GK, Raimondi SC, Hancock ML et al. Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy. Lancet 1991;337:61–66.PubMedCrossRefGoogle Scholar
  7. 7.
    Gaynon PS, Steinherz PG, Bleyer WA et al. Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: a follow-up report of the Childrens Cancer Group Study CCG-106. J Clin Oncol 1993;11:2234–2242.Google Scholar
  8. 8.
    Reiter A, Schrappe M, Ludwig WD et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients: results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994;84:3122–3133.PubMedGoogle Scholar
  9. 9.
    Chessells JM, Bailey C, Richards SM. Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X. Medical Research Council Working Party on Childhood Leukaemia. Lancet 1995;345:143–148.PubMedCrossRefGoogle Scholar
  10. 10.
    Conter V, Arico M, Valsecchi MG et al. Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Haematologica 1998;83:791–799.PubMedGoogle Scholar
  11. 11.
    Evans WE, Relling MV, Rodman JH et al. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 1998;338:499–505.PubMedCrossRefGoogle Scholar
  12. 12.
    Gustafsson G, Kreuger A, Clausen N et al. Intensified treatment of acute childhood lymphoblastic leukaemia has improved prognosis, especially in non-high-risk patients: the Nordic experience of 2648 patients diagnosed between 1981 and 1996. Nordic Society of Pediatric Haematology and Oncology (NOPHO). Acta Paediatr 1998;87:1151–1161.PubMedCrossRefGoogle Scholar
  13. 13.
    Kamps WA, Bokkerink JP, Hahlen K et al. Intensive treatment of children with acute lymphoblastic leukemia according to ALL-BFM-86 without cranial radiotherapy: results of the Dutch Childhood Leukemia Study Group protocol ALL-7 (1988‑91). Blood 1999;94:1226–1236.PubMedGoogle Scholar
  14. 14.
    Sackmann-Muriel F, Felice MS, Zubizarreta PA et al. Treatment results in childhood acute lymphoblastic leukemia with a modified ALL-BFM 90 protocol: lack of improvement in high-risk group. Leuk Res 1999;23:331–340.PubMedCrossRefGoogle Scholar
  15. 15.
    Schrappe M, Reiter A, Ludwig WD et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. Blood 2000;95:3310–3322.PubMedGoogle Scholar
  16. 16.
    Henze G, Langermann HJ, Kaufmann U et al. Thymic involvement and initial white blood count in childhood acute lymphoblastic leukemia. Am J Pediatr Hematol Oncol 1981;3:369–376.PubMedGoogle Scholar
  17. 17.
    Riehm H, Gadner H, Henze G. Acute lymphoblastic leukemia: treatment results in three BFM studies (1970–1981). In: Leukemia research: advances in cell biology and treatment. (Murphy SB, Gilbert JR, eds.), Amsterdam: Elsevier Science Publishing, 1983:251–163.Google Scholar
  18. 18.
    Pinkel D, Woo S. Prevention and treatment of meningeal leukemia in children. Blood 1994;84: 355–366.PubMedGoogle Scholar
  19. 19.
    Clarke M, Gaynon P, Hann Is et al. CNS-directed therapy for childhood acute lymphoblastic leukemia: childhood group collaborative group overview of 43 randomized trials. J Clin Oncol 2003;21: 1798–1809.PubMedCrossRefGoogle Scholar
  20. 20.
    Bene MC, Castoldi G, Knapp W et al. Proposals for the immunological classification of acute leukaemias. European group for the immunological characterisation of leukaemias (EGIL). Leukemia 1995;9:1783–1786.PubMedGoogle Scholar
  21. 21.
    Hiddemann W, Wormann B, Ritter J et al. Frequency and clinical significance of DNA aneuploidy in acute leukemia. Ann NY Acad Sci 1986;468:227–240.PubMedCrossRefGoogle Scholar
  22. 22.
    Pui CH, Williams DL, Raimondi SC et al. Hypodiploidy is associated with a poor prognosis in childhood acute lymphoblastic leukemia. Blood 1987;70:247–253.PubMedGoogle Scholar
  23. 23.
    Fletcher JA, Lynch EA, Kimball VM et al. Translocation t(9;22) is associated with extremely poor prognosis in intensively treated children with acute lymphoblastic leukemia. Blood 1991;77:435–439.PubMedGoogle Scholar
  24. 24.
    Trueworthy R, Shuster J, Look T et al. Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: a Pediatric Oncology Group Study. J Clin Oncol 1992;10:606–613.PubMedGoogle Scholar
  25. 25.
    Harris MB, Shuster JJ, Carroll A et al. Trisomy of leukemic cells chromosomes 4 and 10 identifies children with B-progenitor cell acute lymphoblastic leukemia with a very low risk of treatment failure: a Pediatric Oncology Group study. Blood 1992;79:3316–3324.PubMedGoogle Scholar
  26. 26.
    Harbott J, Ritterbach J, Ludwig W-D et al. Clinical significance of cytogenetic studies in childhood acute lymphoblastic leukemia: experience of the BFM trials. Recent Results in Cancer Research 1993;131:123–132.PubMedGoogle Scholar
  27. 27.
    Pui CH, Rivera GK, Hancock ML et al. Clinical significance of CD10 expression in childhood acute lymphoblastic leukemia. Leukemia 1993;7:35–40.PubMedGoogle Scholar
  28. 28.
    Ludwig W-D, Harbott J, Bartram CR et al. Incidence and prognostic significance of immunophenotypic subgroups in childhood acute lymphoblastic leukemia: experience of the BFM study 86. In: Recent Advances in Cell Biology of Acute Leukemia: Impact on Clinical Diagnosis and Therapy (Ludwig W-D, Thiel E, eds.), Berlin: Springer Verlag, 1993:269–282.Google Scholar
  29. 29.
    Rubnitz JE, Link MP, Shuster JJ et al. Frequency and prognostic significance of HRX rearrangements in infant acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 1994;84:570–573.PubMedGoogle Scholar
  30. 30.
    Behm FG, Raimondi SC, Frestedt JL et al. Rearrangement of the MLL gene confers a poor prognosis in childhood acute lymphoblastic leukemia, regardless of presenting age. Blood 1996;87:2870–2877.PubMedGoogle Scholar
  31. 31.
    Schlieben S, Borkhardt A, Reinisch I et al. Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL): a prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM 90 and CoALL-05-92. Leukemia 1996;10:957–963.PubMedGoogle Scholar
  32. 32.
    Borkhardt A, Cazzaniga G, Viehmann S et al. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin–Frankfurt–Munster Study Group. Blood 1997; 90:571–577.PubMedGoogle Scholar
  33. 33.
    Trka J, Zuna J, Hrusak O et al. Impact of TEL/AML1-positive patients on age distribution of childhood acute lymphoblastic leukemia in Czech Republic. Leukemia 1998;12:996–1007.PubMedCrossRefGoogle Scholar
  34. 34.
    Loh ML, Silverman LB, Young ML et al. Incidence of TEL/AML1 fusion in children with relapsed acute lymphoblastic leukemia. Blood 1998;15:4792–4797.Google Scholar
  35. 35.
    Uckun FM, Sensel MG, Sun L et al. Biology and treatment of childhood T-lineage acute lymphoblastic leukemia. Blood 1998;91:735–746.PubMedGoogle Scholar
  36. 36.
    Heerema NA, Nachman JB, Sather HN et al. Hypodiploidy with less than 45 chromosomes confers adverse risk in childhood acute lymphoblastic leukemia: a report from the Childrens’ Cancer Group. Blood 1999;94:4036–4045.Google Scholar
  37. 37.
    Pui CH, Boyett JM, Relling MV et al. Sex differences in prognosis for children with acute lymphoblastic leukemia. J Clin Oncol 1999;17:818–824.PubMedGoogle Scholar
  38. 38.
    Gajjar A, Harrison PL, Sandlund JT et al. Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. Blood 2000;96:3381–3384.PubMedGoogle Scholar
  39. 39.
    Breit S, Stanulla M, Flohr T et al. Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. Blood 2006;108:1151–1157.PubMedCrossRefGoogle Scholar
  40. 40.
    Riehm H, Reiter A, Schrappe M et al. Die Corticosteroid-abhängige Dezimierung der Leukämiezellzahl im Blut als Prognosefaktor bei der akuten lymphoblastischen Leukämie im Kindesalter (Therapiestudie ALL-BFM 83). (The in vivo response on corticosteroid therapy as an additional prognostic factor in childhood acute lymphoblastic leukemia (therapy study ALL-BFM 83). Klin Pädiatr 1987;199:151–160.PubMedCrossRefGoogle Scholar
  41. 41.
    Gaynon PS, Bleyer WA, Steinherz PG et al. Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features. Med Pediatr Oncol 1990;18: 273–279.PubMedCrossRefGoogle Scholar
  42. 42.
    Janka-Schaub GE, Stührk H, Kortüm B et al. Bone marrow blast count at day 28 as the single most important prognostic factor in childhood acute lymphoblastic leukemia. Haematol Blood Transfus 1992; 34:233–237.Google Scholar
  43. 43.
    Arico M, Basso G, Mandelli F et al. Good steroid response in vivo predicts a favorable outcome in children with T-cell acute lymphoblastic leukemia. Cancer 1995;75:1684–1693.PubMedCrossRefGoogle Scholar
  44. 44.
    Gajjar A, Ribeiro R, Hancock ML et al. Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia. Blood 1995;86:1292–1295.PubMedGoogle Scholar
  45. 45.
    Steinherz PG, Gaynon PS, Breneman JC et al. Cytoreduction and prognosis in acute lymphoblastic leukaemia: the importance of early marrow response: report from the Childrens Cancer Group. J Clin Oncol 1996;14:389–398.Google Scholar
  46. 46.
    Schrappe M, Reiter A, Riehm H. Cytoreduction and prognosis in childhood acute lymphoblastic leukemia. J Clin Oncol 1996;14:2403–2406.PubMedGoogle Scholar
  47. 47.
    Gaynon PS, Desai AA, Bostrom BC et al. Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review. Cancer 1997;80:1717–1726.PubMedCrossRefGoogle Scholar
  48. 48.
    Kaspers GJ, Pieters R, Van Zantwijk CH et al. Prednisolone resistance in childhood acute lymphoblastic leukemia: vitro–vivo correlations and cross-resistance to other drugs. Blood 1998;92:259–266.PubMedGoogle Scholar
  49. 49.
    Brisco MJ, Condon J, Hughes E et al. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction. Lancet 1994;343:196–200.PubMedCrossRefGoogle Scholar
  50. 50.
    Cave H, van der Werff ten Bosch J, Suciu S et al. European Organization for Research and Treatment of Cancer–Childhood Leukemia Cooperative Group. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. N Engl J Med 1998;339:591–598.Google Scholar
  51. 51.
    van Dongen JJ, Seriu T, Panzer-Grümayer ER et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998;352:1731–1738.PubMedCrossRefGoogle Scholar
  52. 52.
    Ciudad J, San Miguel JF, López-Berges MC et al. Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia. J Clin Oncol 1998;16:3774–3781.PubMedGoogle Scholar
  53. 53.
    Foroni L, Harrison JC, Hoffbrand AV et al. Investigation of minimal residual disease in chidhood and adult acute lymphoblastic leukemia by molecular analysis. Br J Haematol 1999;105:7–24.PubMedGoogle Scholar
  54. 54.
    Coustan-Smith E, Sancho J, Hancock ML et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000;96:2691–2696.PubMedGoogle Scholar
  55. 55.
    Dworzak MN, Fröschl G, Printz D et al. Austrian Berlin–Frankfurt–Münster Study Group. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood 2002;99:1952–1958.PubMedCrossRefGoogle Scholar
  56. 56.
    Nyvold C, Madsen HO, Ryder LP et al. Nordic Society for Pediatric Hematology and Oncology. Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome. Blood 2002;99:1253–1258.PubMedCrossRefGoogle Scholar
  57. 57.
    Bürger B, Zimmermann M, Mann G et al. Diagnostic cerebrospinal fluid (CSF) examination in children with acute lymphoblastic leukemia (ALL): significance of low leukocyte counts with blasts or traumatic lumbar puncture. J Clin Oncol 2003;21:184–188.PubMedCrossRefGoogle Scholar
  58. 58.
    Mastrangelo R, Poplack D, Bleyer A et al. Report and recommendations of the Rome workshop concerning poor-prognosis acute lymphoblastic leukemia in children: biologic bases for staging, stratification, and treatment. Med Pediatr Oncol 1986;14:191–194.Google Scholar
  59. 59.
    van der Does-van den Berg A, Bartram CR, Basso G et al. Minimal requirements for the diagnosis, classification, and evaluation of the treatment of childhood acute lymphoblastic leukemia (ALL) in the “BFM Family” Cooperative Group. Med Pediatr Oncol 1992;20:497–505.Google Scholar
  60. 60.
    Smith M, Arthur D, Camitta B et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996;14:18–24.PubMedGoogle Scholar
  61. 61.
    Elion GB, Burgi E, Hitchings GH. Studies on condensed pyrimidine systems, IX: the synthesis of some 6-substituted purines. J Am Chem Soc 1952;74:411–414.CrossRefGoogle Scholar
  62. 62.
    Burchenal JH, Murphy ML, Ellison RR et al. Clinical evaluation of a new antimetabolite, 6-mercaptopurine, in the treatment of leukemia and allied diseases. Blood 1953;8:965–999.PubMedGoogle Scholar
  63. 63.
    Bertino JR. Improving the curability of acute leukemia: pharmacologic approaches. Semin Hematology 1991;28:9–11.Google Scholar
  64. 64.
    McLeod HL, Krynetski EY, Relling MV et al. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 2000;14:567–572.PubMedCrossRefGoogle Scholar
  65. 65.
    Bokkering J, Damen F, Huylscher M et al. Biochemical evidence for synergistic combination treatment with methotrexate and 6-mercaptopurine in childhood acute lymphoblastic leukemia. Haematol Blood Transfus 1990;33:110–117.Google Scholar
  66. 66.
    Giverhaug T, Loennechen T, Aarbakke J. Increased concentrations of methylated 6-mercaptopurine metabolites and 6-thioguanine nucleotides in human leukemic cells in vitro by methotrexate. Biochem Pharmacol 1998; 55:1641–1646.PubMedCrossRefGoogle Scholar
  67. 67.
    Dervieux T, Brenner TL, Hon YY et al. De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo. Blood 2002;100:1240–1247.PubMedCrossRefGoogle Scholar
  68. 68.
    Dervieux T, Hancock ML, Evans WE et al. Effect of methotrexate polyglutamates on thioguanine nucleotide concentrations during continuation therapy of acute lymphoblastic leukemia with mercaptopurine. Leukemia 2002;16:209–212.PubMedCrossRefGoogle Scholar
  69. 69.
    Dervieux T, Hancock ML, Pui CH et al. Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia. Clin Pharmacol Ther 2003;73:506–516.PubMedCrossRefGoogle Scholar
  70. 70.
    van der Werff Ten Bosch J, Suciu S, Thyss A et al. Value of intravenous 6-mercaptopurine during continuation treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma: final results of a randomized phase III trial (58881) of the EORTC CLG. Leukemia 2005;19:721–726.PubMedCrossRefGoogle Scholar
  71. 71.
    Tolar J, Bostrom BC, La MK, Sather HN. Intravenous 6-mercaptopurine decreases salvage after relapse in childhood acute lymphoblastic leukemia: a report from the Childrens’ Cancer Group study CCG 1922. Pediatr Blood Cancer 2005;45:5–9.Google Scholar
  72. 72.
    Ferrazzini G, Klein J, Sulh H et al. Interaction between trimethoprim-sulfamethoxazole and methotrexate in children with leukemia. J Pediatr 1990;117:823–826.PubMedCrossRefGoogle Scholar
  73. 73.
    Beach BJ, Woods WG, Howell SB. Influence of cotrimoxazole on methotrexate pharmacokinetics in children with acute lymphoblastic leukemia. Am J Pediatr Hematol Oncol 1981;3:115–119.PubMedCrossRefGoogle Scholar
  74. 74.
    Rivard GE, Infante-Rivard C, Dresse MF et al. Circadian time-dependent response of childhood lymphoblastic leukemia to chemotherapy: a long-term follow-up study of survival. Chronobiol Int 1993;10:201–204.PubMedCrossRefGoogle Scholar
  75. 75.
    Schmiegelow K, Glomstein A, Kristinsson J et al. Impact of morning versus evening schedule for oral methotrexate and 6-mercaptopurine on relapse risk for children with acute lymphoblastic leukemia. Nordic Society for Pediatric Hematology and Oncology (NOPHO). J Pediatr Hematol Oncol 1997;19:102–109.PubMedCrossRefGoogle Scholar
  76. 76.
    Rivard GE, Lin KT, Leclerc JM et al. Milk could decrease the bioavailability of 6-mercaptopurine. Am J Pediatr Hematol Oncol 1989;11:402–406.PubMedGoogle Scholar
  77. 77.
    Riccardi R, Balis FM, Ferrara P et al. Influence of food intake on bioavailability of oral 6-mercaptopurine in children with acute lymphoblastic leukemia. Pediatr Hematol Oncol 1986;3: 319–324.PubMedCrossRefGoogle Scholar
  78. 78.
    Sofianou-Katsoulis A, Khakoo G, Kaczmarski R. Reduction in bioavailability of 6-mercaptopurine on simultaneous administration with cow's milk. Pediatr Hematol Oncol 2006;23:485–487.PubMedCrossRefGoogle Scholar
  79. 79.
    Relling MV, Hancock ML, Boyett JM et al. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood 1999;93:2817–2823.PubMedGoogle Scholar
  80. 80.
    Rees CA, Lennard L, Lilleyman JS et al. Disturbance of 6-mercaptopurine metabolism by cotrimoxazole in childhood lymphoblastic leukaemia. Cancer Chemother Pharmacol 1984;12:87–89.PubMedCrossRefGoogle Scholar
  81. 81.
    Burton NK, Aherne GW. The effect of cotrimoxazole on the absorption of orally administered 6-mercaptopurine in the rat. Cancer Chemother Pharmacol 1986;16:83–84.PubMedCrossRefGoogle Scholar
  82. 82.
    Childhood ALL Collaborative Group. Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12 000 randomised children. Lancet 1996;347:1783–1788.Google Scholar
  83. 83.
    Mitchell CD, Richards SM, Kinsey SE. Medical Research Council Childhood Leukaemia Working Party. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol 2005;129:734–745.PubMedCrossRefGoogle Scholar
  84. 84.
    Conter V, Valsecchi MG, Silvestri D et al. Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial. Lancet 2007;369:123–131.PubMedCrossRefGoogle Scholar
  85. 85.
    Riehm H, Gadner H, Henze G. Results and significance of six randomized trials in four consecutive ALL-BFM trials. In: Haematology and Blood Transfusion, Vol. 33, Acute Leukemias II (Büchner T, Schellong G, Hiddemann W et al., eds.), Berlin: Springer-Verlag, 1990:439–450.Google Scholar
  86. 86.
    Harms DO, Gobel U, Spaar HJ et al. COALL Study Group. Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: results of the randomized trial COALL-92. Blood 2003;102:2736–2740.PubMedCrossRefGoogle Scholar
  87. 87.
    Vora A, Mitchell CD, Lennard L et al. Medical Research Council. National Cancer Research Network Childhood Leukaemia Working Party. Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial. Lancet 2006;368:1339–1348.PubMedCrossRefGoogle Scholar
  88. 88.
    Stork LC, Sather H, Hutchinson RJ et al. Comparison of mercaptopurine (MP) with thioguanine (TG) and IT methotrexate (ITM) with IT “triples” (ITT) in children with SR-ALL: results of CCG-1952. Blood 2002;100:156a.Google Scholar
  89. 89.
    de Boer NK, Reinisch W, Teml A et al. Dutch 6-TG Working Group. 6-Thioguanine treatment in inflammatory bowel disease: a critical appraisal by a European 6-TG working party. Digestion 2006;73:25–31.PubMedCrossRefGoogle Scholar
  90. 90.
    Aarbakke J, Janka-Schaub G, Elion GB. Thiopurine biology and pharmacology. Trends Pharmacol Sci 1997;18:3–7.PubMedCrossRefGoogle Scholar
  91. 91.
    Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992;43:329–339.PubMedCrossRefGoogle Scholar
  92. 92.
    Teml A, Schaeffeler E, Herrlinger KR et al. Thiopurine treatment in inflammatory bowel diseases: clinical pharmacology and implication of pharmacogenetically guided dosing. Clin Pharmacokinet 2007;46:187–208.Google Scholar
  93. 93.
    Elion GB. The George Hitchings and Gertrude Elion Lecture. The pharmacology of azathioprine. Ann NY Acad Sci 1993;685:400–407.PubMedCrossRefGoogle Scholar
  94. 94.
    Lennard L, Van Loon JA, Lilleyman JS et al. Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol Ther 1987;41:18–25.PubMedCrossRefGoogle Scholar
  95. 95.
    Maybaum J, Mandel HG. Differential chromatid damage induced by 6-thioguanine in CHO cells. Exp Cell Res 1981;135:465–468.PubMedCrossRefGoogle Scholar
  96. 96.
    Christie NT, Drake S, Meyn RE et al. 6-Thioguanine-induced DNA damage as a determinant of cytotoxicity in cultured Chinese hamster ovary cells. Cancer Res 1984;44:3665–3671.PubMedGoogle Scholar
  97. 97.
    Pan BF, Nelson JA. Characterization of the DNA damage in 6-thioguanine-treated cells. Biochem Pharmacol 1990;40:1063–1069.PubMedCrossRefGoogle Scholar
  98. 98.
    Bodell WJ. Molecular dosimetry of sister chromatid exchange induction in 9 L cells treated with 6-thioguanine. Mutagenesis 1991;6:175–177.PubMedCrossRefGoogle Scholar
  99. 99.
    Somerville L, Krynetski EY, Krynetskaia NF et al. Structure and dynamics of thioguanine-modified duplex DNA. J Biol Chem 2003;278:1005–1011.Google Scholar
  100. 100.
    Swann PF, Waters TR, Moulton DC et al. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science 1996;273:1109–1111.PubMedCrossRefGoogle Scholar
  101. 101.
    Vogt MH, Stet EH, De Abreu RA et al. The importance of methylthio-imp for methylmercaptopurine ribonucleoside (Me-MPR) cytotoxicity in molt F4 human malignant T-lymphoblasts. Biochim Biophys Acta 1993;1181:189–194.PubMedGoogle Scholar
  102. 102.
    Tidd DM, Kim SC, Horakova K et al. A delayed cytotoxic reaction for 6-mercaptopurine. Cancer Res 1972;32:317–322.PubMedGoogle Scholar
  103. 103.
    Dervieux T, Blanco JG, Krynetski EY et al. Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells. Cancer Res 2001;61:5810–5816.PubMedGoogle Scholar
  104. 104.
    Tiede I, Fritz G, Strand S et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003;111:1133–1145.PubMedGoogle Scholar
  105. 105.
    Neurath MF, Kiesslich R, Teichgräber Ul et al. 6-Thioguanosine diphosphate and triphosphate levels in red blood cells and response to azathioprine therapy in Crohn's disease. Clin Gastroenterol Hepatol 2005;3:1007–1014.PubMedCrossRefGoogle Scholar
  106. 106.
    Poppe D, Tiede I, Fritz G et al. Azathioprine suppresses ezrin-radixin-moesin-dependent T-cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J Immunol 2006;176:640–651.PubMedGoogle Scholar
  107. 107.
    Loo TL, Luce JK, Sullivan MP et al. Clinical pharmacologic observations on 6-mercaptopurine and 6-methylthiopurine ribonucleoside. Clin Pharmacol Ther 1968;9:180–194.PubMedGoogle Scholar
  108. 108.
    LePage GA, Whitecar JP. Pharmacology of 6-thioguanine in man. Cancer Res 1971;31:1627–1631.PubMedGoogle Scholar
  109. 109.
    Konits PH, Egorin MJ, Van Echo DA et al. Phase II evaluation and plasma pharmacokinetics of high-dose intravenous 6-thioguanine in patients with colorectal carcinoma. Cancer Chemother Pharmacol 1982;8:199–203.PubMedCrossRefGoogle Scholar
  110. 110.
    Balis FM, Holcenberg JS, Poplack DG et al. Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint Childrens’ Cancer Group and Pediatric Oncology Branch study. Blood 1998;92:3569–3577.PubMedGoogle Scholar
  111. 111.
    Erb N, Harms DO, Janka-Schaub G. Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine. Cancer Chemother Pharmacol 1998;42:266–272.PubMedCrossRefGoogle Scholar
  112. 112.
    Lennard L, Lilleyman JS. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol 1989;7:1816–1823. Erratum in: J Clin Oncol 1990;8:567.PubMedGoogle Scholar
  113. 113.
    Lennard L, Lewis IJ, Michelagnoli M et al. Thiopurine methyltransferase deficiency in childhood lymphoblastic leukaemia: 6-mercaptopurine dosage strategies. Med Pediatr Oncol 1997;29:252–255.PubMedCrossRefGoogle Scholar
  114. 114.
    Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989;46: 149–154.CrossRefGoogle Scholar
  115. 115.
    Lavi LE, Holcenberg JS. A rapid and sensitive high-performance liquid chromatographic assay for 6-mercaptopurine metabolites in red blood cells. Anal Biochem 1985;144:514–521.PubMedCrossRefGoogle Scholar
  116. 116.
    Lennard L. Assay of 6-thioinosinic acid and 6-thioguanine nucleotides, active metabolites of 6-mercaptopurine, in human red blood cells. J Chomatogr 1987;423:169–178.Google Scholar
  117. 117.
    Lennard L, Singleton HJ. High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid, and 6-methylmercaptopurine metabolites in a single sample. J Chromatogr 1992;583:83–90.PubMedCrossRefGoogle Scholar
  118. 118.
    Keuzenkamp-Jansen CW, De Abreu RA, Bokkerink JP et al. Determination of extracellular and intracellular thiopurines and methylthiopurines by high-performance liquid chromatography. J Chromatogr B Biomed Appl 1995;672:53–61.PubMedCrossRefGoogle Scholar
  119. 119.
    Dervieux T, Boulieu R. Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC. Clin Chem 1998;44:551–555.PubMedGoogle Scholar
  120. 120.
    Dervieux T, Chu Y, Su Y et al. HPLC determination of thiopurine nucleosides and nucleotides in vivo in lymphoblasts following mercaptopurine therapy. Clin Chem 2002;48:61–68.PubMedGoogle Scholar
  121. 121.
    Stefan C, Walsh W, Banka T et al. Improved HPLC methodology for monitoring thiopurine metabolites in patients on thiopurine therapy. Clin Biochem 2004;37:764–771.PubMedCrossRefGoogle Scholar
  122. 122.
    Shipkova M, Armstrong VW, Wieland E et al. Differences in nucleotide hydrolysis contribute to the differences between erythrocyte 6-thioguanine nucleotide concentrations determined by two widely used methods. Clin Chem 2003;49:260–268.PubMedCrossRefGoogle Scholar
  123. 123.
    Lilleyman JS, Lennard L. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia. Lancet 1994;343:1188–1190.PubMedCrossRefGoogle Scholar
  124. 124.
    Schmiegelow K, Schroder H, Gustafsson G et al. Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology. J Clin Oncol 1995;13: 345–351.PubMedGoogle Scholar
  125. 125.
    Lancaster D, Patel N, Lennard L et al. Leucocyte versus erythrocyte thioguanine nucleotide concentrations in children taking thiopurines for acute lymphoblastic leukaemia. Cancer Chemother Pharmacol 2002;50:33–36.PubMedCrossRefGoogle Scholar
  126. 126.
    Rowland K, Lennard L, Lilleyman JS. In vitro metabolism of 6-mercaptopurine by human liver cytosol. Xenobiotica 1999;29:615–628.PubMedCrossRefGoogle Scholar
  127. 127.
    Bostrom B, Erdmann G. Cellular pharmacology of 6-mercaptopurine in acute lymphoblastic leukemia. Am J Pediatr Hematol Oncol 1993;15:80–86.PubMedCrossRefGoogle Scholar
  128. 128.
    Schmiegelow K, Bjork O, Glomstein A et al. Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia. J Clin Oncol 2003;21:1332–1339.PubMedCrossRefGoogle Scholar
  129. 129.
    Bell BA, Brockway GN, Shuster JJ et al. Pediatric Oncology Group study (now The Children's Oncology Group). A comparison of red blood cell thiopurine metabolites in children with acute lymphoblastic leukemia who received oral mercaptopurine twice daily or once daily: a Pediatric Oncology Group study (now The Childrens’ Oncology Group). Pediatr Blood Cancer 2004;43:105–109.PubMedCrossRefGoogle Scholar
  130. 130.
    Weinshilboum R. Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase. Drug Metab Dispos 2001;29:601–605.PubMedGoogle Scholar
  131. 131.
    Krynetski E, Evans WE. Drug methylation in cancer therapy: lessons from the TPMT polymorphism. Oncogene 2003;22:7403–7413.PubMedCrossRefGoogle Scholar
  132. 132.
    Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980;32:651–662.PubMedGoogle Scholar
  133. 133.
    Vuchetich JP, Weinshilboum RM, Price RA. Segregation analysis of human red blood cell thiopurine methyltransferase activity. Gen Epidemiol 1995;12:1–11.CrossRefGoogle Scholar
  134. 134.
    Coulthard SA, Rabello C, Robson J et al. A comparison of molecular and enzyme-based assays for the detection of thiopurine methyltransferase mutations. Br J Haematol 2000;110:599–604.PubMedCrossRefGoogle Scholar
  135. 135.
    Alves S, Amorim A, Ferreira F et al. Influence of the variable number of tandem repeats located in the promoter region of the thiopurine methyltransferase gene on enzymatic activity. Clin Pharmacol Ther 2001;70:165–174.PubMedCrossRefGoogle Scholar
  136. 136.
    McLeod HL, Lin JS, Scott EP, Pui CH, Evans WE. Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther 1994;55:15–20.PubMedCrossRefGoogle Scholar
  137. 137.
    McLeod HL, Krynetski EY, Wilimas JA et al. Higher activity of polymorphic thiopurine S-methyltransferase in erythrocytes from neonates compared to adults. Pharmacogenetics 1995;5: 281–286.PubMedCrossRefGoogle Scholar
  138. 138.
    Klemetsdal B, Wist E, Aarbakke J. Gender difference in red blood cell thiopurine methyltransferase activity. Scand J Clin Lab Invest 1993;53:747–749.PubMedCrossRefGoogle Scholar
  139. 139.
    Szumlanski CL, Honchel R, Scott MC et al. Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver–erythrocyte correlation and presence of isozymes. Pharmacogenetics 1992;2:148–159.PubMedCrossRefGoogle Scholar
  140. 140.
    Schaeffeler E, Fischer C, Brockmeier D et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics 2004;14:407–417.PubMedCrossRefGoogle Scholar
  141. 141.
    Lennard L, Lilleyman JS, Van Loon J et al. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990;336:225–229.PubMedCrossRefGoogle Scholar
  142. 142.
    Szumlanski CL, Weinshilboum RM. Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol 1995;39:456–459.PubMedGoogle Scholar
  143. 143.
    Xin H-W, Fischer C, Schwab M et al. Effects of aminosalicylates on thiopurine S-methyltransferase activity: an ex vivo study in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2005;21:1105–1109.PubMedCrossRefGoogle Scholar
  144. 144.
    Xin H-W, Fischer C, Schwab M et al. Thiopurine S-methyltransferase as a target for drug interaction. Eur J Clin Pharmacol 2005;61:395–398.PubMedCrossRefGoogle Scholar
  145. 145.
    Weinshilboum RM, Raymond FA, Pazmino PA. Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties. Clin Chim Acta 1978;85:323–333.PubMedCrossRefGoogle Scholar
  146. 146.
    Anglicheau D, Sanquer S, Loriot MA et al. Thiopurine methyltransferase activity: new conditions for reversed-phase high-performance liquid chromatographic assay without extraction and genotypic-phenotypic correlation. J Chromatogr B Analyt Technol Biomed Life Sci 2002;773:119–127.PubMedCrossRefGoogle Scholar
  147. 147.
    Menor C, Fueyo JA, Escribano O et al. Determination of thiopurine methyltransferase activity in human erythrocytes by high-performance liquid chromatography: comparison with the radiochemical method. Ther Drug Monit 2001;23:536–541.PubMedCrossRefGoogle Scholar
  148. 148.
    Lennard L, Singleton HJ. High-performance liquid chromatographic assay of human red blood cell thiopurine methyltransferase activity. J Chromatogr B Biomed Appl 1994;661:25–33.PubMedCrossRefGoogle Scholar
  149. 149.
    Boulieu R, Sauviat M, Dervieux T et al. Phenotype determination of thiopurine methyltransferase in erythrocytes by HPLC. Clin Chem 2001;47:956–958.PubMedGoogle Scholar
  150. 150.
    Indjova D, Shipkova M, Atanasova S et al. Determination of thiopurine methyltransferase phenotype in isolated human erythrocytes using a new simple nonradioactive HPLC method. Ther Drug Monit 2003;25:637–644.PubMedCrossRefGoogle Scholar
  151. 151.
    Kroplin T, Weyer N, Gutsche S et al. Thiopurine S-methyltransferase activity in human erythrocytes: a new HPLC method using 6-thioguanine as substrate. Eur J Clin Pharmacol 1998;54:265–271.PubMedCrossRefGoogle Scholar
  152. 152.
    Kroplin T, Iven H. Methylation of 6-mercaptopurine and 6-thioguanine by thiopurine S-methyltransferase: a comparison of activity in red blood cell samples of 199 blood donors. Eur J Clin Pharmacol 2000;56:343–345.PubMedCrossRefGoogle Scholar
  153. 153.
    Khalil MN, Erb N, Khalil PN et al. Interference free and simplyfied liquid chromatography-based determination of thiopurine S-methyltransferase activity in erythrocytes. J Chromatogr B Analyt Technol Biomed Life Sci 2005;821:105–111. Erratum in: J Chromatogr B Analyt Technol Biomed Life Sci 2005;824:348–350.Google Scholar
  154. 154.
    McLeod HL, Relling MV, Liu Q et al. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood 1995;85:1897–1902.PubMedGoogle Scholar
  155. 155.
    Honchel R, Aksoy IA, Szumlanski C et al. Human thiopurine methyltransferase: molecular cloning and expression of T84 colon carcinoma cell cDNA. Mol Pharmacol 1993;43:878–887.PubMedGoogle Scholar
  156. 156.
    Szumlanski C, Otterness D, Her C et al. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol 1996;15:17–30.PubMedCrossRefGoogle Scholar
  157. 157.
    Krynetski EY, Fessing MY, Yates CR et al. Promoter and intronic sequences of the human thiopurine S-methyltransferase (TPMT) gene isolated from a human Pac1 genomic library. Pharm Res 1997;14:1672–1678.PubMedCrossRefGoogle Scholar
  158. 158.
    Seki T, Tanaka T, Nakamura Y. Genomic structure and multiple single-nucleotide polymorphisms (SNPs) of the thiopurine S-methyltransferase (TPMT) gene. J Hum Genet 2000;45:299–302.PubMedCrossRefGoogle Scholar
  159. 159.
    Krynetski EY, Schuetz JD, Galpin AJ et al. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci USA 1995;92:949–953.PubMedCrossRefGoogle Scholar
  160. 160.
    Tai HL, Krynetski EY, Yates CR et al. Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in caucasians. Am J Hum Genet 1996;58:694–702.PubMedGoogle Scholar
  161. 161.
    Otterness D, Szumlanski C, Lennard L et al. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther 1997;62:60–73.PubMedCrossRefGoogle Scholar
  162. 162.
    Spire-Vayron de la Moureyre C, Debuysere H, Sabbagh N et al. Detection of known and new mutations in the thiopurine S-methyltransferase gene by single-strand conformation polymorphism analysis. Hum Mutat 1998;12:177–185.Google Scholar
  163. 163.
    Hon YY, Fessing MY, Pui CH et al. Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. Hum Mol Genet 1999;8:371–376.PubMedCrossRefGoogle Scholar
  164. 164.
    Colombel JF, Ferrari N, Debuysere H et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000;118:1025–1030.PubMedCrossRefGoogle Scholar
  165. 165.
    Schaeffeler E, Stanulla M, Greil J et al. A novel TPMT missense mutation associated with TPMT deficiency in a 5-year-old boy with ALL. Leukemia 2003;17:1422–1424.PubMedCrossRefGoogle Scholar
  166. 166.
    Hamdan-Khalil R, Allorge D, Lo-Guidice JM et al. In vitro characterization of four novel non-functional variants of the thiopurine S-methyltransferase. Biochem Biophys Res Commun 2003;309:1005–1010.PubMedCrossRefGoogle Scholar
  167. 167.
    Lindqvist M, Haglund S, Almer S et al. Identification of two novel sequence variants affecting thiopurine methyltransferase enzyme activity. Pharmacogenetics 2004;14:261–265.PubMedCrossRefGoogle Scholar
  168. 168.
    Hamdan-Khalil R, Gala JL, Allorge D et al. Identification and functional analysis of two rare allelic variants of the thiopurine S-methyltransferase gene, TPMT∗16, and TPMT∗19. Biochem Pharmacol 2005;69:525–529.PubMedCrossRefGoogle Scholar
  169. 169.
    Schaeffeler E, Eichelbaum M, Reinisch W et al. Three novel thiopurine S-methyltransferase allelic variants (TPMT∗20, ∗21, ∗22)-association with decreased enzyme function. Hum Mutat 2006;27:976.PubMedCrossRefGoogle Scholar
  170. 170.
    Yates CR, Krynetski EY, Loennechen T et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997;126:608–614.PubMedGoogle Scholar
  171. 171.
    McLeod HL, Pritchard SC, Githang'a J et al. Ethnic differences in thiopurine methyltransferase pharmacogenetics: evidence for allele specificity in Caucasian and Kenyan individuals. Pharmacogenetics 1999;9:773–776.PubMedCrossRefGoogle Scholar
  172. 172.
    Collie-Duguid ES, Pritchard SC, Powrie RH et al. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 1999;9:37–42.PubMedCrossRefGoogle Scholar
  173. 173.
    Salavaggione OE, Wang L, Wiepert M et al. Thiopurine S-methyltransferase pharmacogenetics: variant allele functional and comparative genomics. Pharmacogenet Genomics 2005;15:801–815.PubMedCrossRefGoogle Scholar
  174. 174.
    Tai HL, Krynetski EY, Schuetz EG et al. Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT3A, TPMT2): mechanisms for the genetic polymorphism of TPMT activity. Proc Natl Acad Sci USA 1997;94:6444–6449.PubMedCrossRefGoogle Scholar
  175. 175.
    Tai HL, Fessing MY, Bonten EJ et al. Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cells: mechanism for TPMT protein deficiency inherited by TPMT2, TPMT3A, TPMT3B or TPMT3C. Pharmacogenetics 1999;9:641–650.PubMedCrossRefGoogle Scholar
  176. 176.
    Wang L, Sullivan W, Toft D et al. Thiopurine S-methyltransferase pharmacogenetics: chaperone protein association and allozyme degradation. Pharmacogenetics 2003;13:555–564.PubMedCrossRefGoogle Scholar
  177. 177.
    Wang L, Nguyen TV, McLaughlin RW et al. Human thiopurine S-methyltransferase pharmacogenetics: variant allozyme misfolding and aggresome formation. Proc Natl Acad Sci USA 2005;102: 9394–9399.PubMedCrossRefGoogle Scholar
  178. 178.
    Seki T, Tanaka T, Nakamura Y. Genomic structure and multiple single-nucleotide polymorphisms (SNPs) of the thiopurine S-methyltransferase (TPMT) gene. J Hum Genet 2000;45:299–302.PubMedCrossRefGoogle Scholar
  179. 179.
    Fessing MY, Krynetski EY, Zambetti GP et al. Functional characterization of the human thiopurine S-methyltransferase (TPMT) gene promoter. Eur J Biochem 1998;256:510–517.PubMedCrossRefGoogle Scholar
  180. 180.
    Spire-Vayron de la Moureyre C, Debuysere H, Fazio F et al. Characterization of a variable number tandem repeat region in the thiopurine S-methyltransferase gene promoter. Pharmacogenetics 1999;9:189–198.Google Scholar
  181. 181.
    Alves S, Amorim A, Ferreira F et al. Influence of the variable number of tandem repeats located in the promoter region of the thiopurine methyltransferase gene on enzymatic activity. Clin Pharmacol Ther 2001;70:165–174.PubMedCrossRefGoogle Scholar
  182. 182.
    Yan L, Zhang S, Eiff B et al. Thiopurine methyltransferase polymorphic tandem repeat: genotype–phenotype correlation analysis. Clin Pharmacol Ther 2000;68:210–219.PubMedCrossRefGoogle Scholar
  183. 183.
    Marinaki AM, Arenas M, Khan ZH et al. Genetic determinants of the thiopurine methyltransferase intermediate activity phenotype in British Asians and Caucasians. Pharmacogenetics 2003;13: 97–105.PubMedCrossRefGoogle Scholar
  184. 184.
    Lee D, Szumlanski C, Houtman J et al. Thiopurine methyltransferase pharmacogenetics: cloning of human liver cDNA and a processed pseudogene on human chromosome 18q21.1. Drug Metab Dispos 1995;23:398–405.PubMedGoogle Scholar
  185. 185.
    Schaeffeler E, Lang T, Zanger UM et al. High-throughput genotyping of thiopurine S-methyltransferase by denaturing HPLC. Clin Chem 2001;47:548–555.PubMedGoogle Scholar
  186. 186.
    Hall AG, Hamilton P, Minto L et al. The use of denaturing high-pressure liquid chromatography for the detection of mutations in thiopurine methyltransferase. J Biochem Biophys Methods 2001;47:65–71.PubMedCrossRefGoogle Scholar
  187. 187.
    Davison JE, McMullin MF, Catherwood MA. Genotyping of thiopurine methyltransferase in patients with acute leukemia using LightCycler PCR. Leuk Lymphoma 2006;47:1624–1628.PubMedCrossRefGoogle Scholar
  188. 188.
    Lindqvist M, Almer S, Peterson C et al. Real-time RT-PCR methodology for quantification of thiopurine methyltransferase gene expression. Eur J Clin Pharmacol 2003;59:207–211.PubMedCrossRefGoogle Scholar
  189. 189.
    Lu Y, Kham SK, Tan PL et al. Arrayed primer extension: a robust and reliable genotyping platform for the diagnosis of single gene disorders: beta-thalassemia and thiopurine methyltransferase deficiency. Genet Test 2005;9:212–219.PubMedCrossRefGoogle Scholar
  190. 190.
    McDonald OG, Krynetski EY, Evans WE. Molecular haplotyping of genomic DNA for multiple single-nucleotide polymorphisms located kilobases apart using long-range polymerase chain reaction and intramolecular ligation. Pharmacogenetics 2002;12:93–99.PubMedCrossRefGoogle Scholar
  191. 191.
    Ford L, Graham V, Berg J. Whole-blood thiopurine S-methyltransferase activity with genotype concordance: a new, simplified phenotyping assay. Ann Clin Biochem 2006;43:354–360.PubMedCrossRefGoogle Scholar
  192. 192.
    Haglund S, Lindqvist M, Almer S et al. Pyrosequencing of TPMT alleles in a general Swedish population and in patients with inflammatory bowel disease. Clin Chem 2004;50:288-295. Erratum in: Clin Chem 2004;50:788.Google Scholar
  193. 193.
    Nasedkina TV, Fedorova OE, Glotov AS et al. Rapid genotyping of common deficient thiopurine S-methyltransferase alleles using the DNA-microchip technique. Eur J Hum Genet 2006;14:991–998.PubMedCrossRefGoogle Scholar
  194. 194.
    Brouwer C, Marinaki AM, Lambooy LH et al. Pitfalls in determination of mutant alleles in the thiopurine methyltransfrase gene. Leukemia 2001;15:1792–1793.PubMedGoogle Scholar
  195. 195.
    Coulthard SA, Howell C, Robson J et al. The relationship between thiopurine methyltransferase activity and genotype in blasts from patients with acute leukemia. Blood 1998;92:2856–2862.PubMedGoogle Scholar
  196. 196.
    Lennard L, Gibson BE, Nicole T et al. Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. Arch Dis Child 1993;69:577–579.PubMedCrossRefGoogle Scholar
  197. 197.
    McLeod HL, Coulthard S, Thomas AE et al. Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia. Br J Haematol 1999;105:696–700.PubMedCrossRefGoogle Scholar
  198. 198.
    Relling MV, Hancock ML, Rivera GK et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999;91:2001–2008.PubMedCrossRefGoogle Scholar
  199. 199.
    Andersen JB, Szumlanski C, Weinshilboum RM et al. Pharmacokinetics, dose adjustments, and 6-mercaptopurine/methotrexate drug interactions in two patients with thiopurine methyltransferase deficiency. Acta Paediatr 1998;87:108–111.PubMedCrossRefGoogle Scholar
  200. 200.
    Evans WE, Horner M, Chu YQ et al. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr 1991;119:985–989.PubMedCrossRefGoogle Scholar
  201. 201.
    Kaskas BA, Louis E, Hindorf U et al. Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine. Gut 2003;52:140–142.PubMedCrossRefGoogle Scholar
  202. 202.
    Evans WE, Hon YY, Bomgaars L et al. Preponderance of thiopurine S-methyl-transferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 2001;19:2293–2301.PubMedGoogle Scholar
  203. 203.
    Relling MV, Yanishevski Y, Nemec J et al. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia 1998;12:346–352.PubMedCrossRefGoogle Scholar
  204. 204.
    Relling MV, Rubnitz JE, Rivera GK et al. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet 1999;354:34–39.PubMedCrossRefGoogle Scholar
  205. 205.
    Relling MV, Pui CH, Cheng C et al. Thiopurine methyltransferase in acute lymphoblastic leukemia. Blood 2006;107:843–844.PubMedCrossRefGoogle Scholar
  206. 206.
    Stanulla M, Schaeffeler E, Flohr T et al. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA 2005;293:1485–1489.PubMedCrossRefGoogle Scholar
  207. 207.
    Thomsen BJ, Schroder H, Kristinsson J et al. Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: relation to thiopurine metabolism. Cancer 1999;86:1080–1086.CrossRefGoogle Scholar
  208. 208.
    Stanulla M, Schaeffeler E, Moricke A et al. Thiopurine methyltransferase genotype is not a risk factor for secondary malignant neoplasias after treatment for childhood acute lymphoblastic leukemia on Berlin FrankfurtMünster protocols. Blood 2006;108:48a.Google Scholar
  209. 209.
    Lennard L, Richards S, Cartwright CS et al. UK MRC/NCRI Childhood Leukaemia Working Party. The thiopurine methyltransferase genetic polymorphism is associated with thioguanine-related veno-occlusive disease of the liver in children with acute lymphoblastic leukemia. Clin Pharmacol Ther 2006;80:375–383.PubMedCrossRefGoogle Scholar
  210. 210.
    Alves S, Prata MJ, Ferreira F et al. Thiopurine methyltrarisferase pharmacogenetics: alternative molecular diagnosis and preliminary data from Northern Portugal. Pharmacogenetics 1999;9:257–261.Google Scholar

Copyright information

© Humana Press, a part of Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Martin Stanulla
    • 1
  • Elke Schaeffeler
    • 2
  • Matthias Schwab
    • 3
  1. 1.Pediatric Hematology Oncology Hannover Medical SchoolHannoverGermany
  2. 2.Margarete-Fischer-Bosch Institute of Clinical PharmacologyStuttgartGermany
  3. 3.Department of Clinical PharmacologyUniversity Hospital TuebingenTubingenGermany

Personalised recommendations